New hope for kidney cancer: drug combo targets tumors after immunotherapy fails

NCT ID NCT07165418

Not yet recruiting Disease control Sponsor: Peking University Cancer Hospital & Institute Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This phase 3 trial tests whether a combination of two drugs, vorolanib and everolimus, can help people with advanced kidney cancer whose disease has worsened after immunotherapy. About 116 participants will be randomly assigned to receive either the combo or the standard drug sunitinib. The goal is to see if the combo can delay cancer growth and improve survival.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: vorolanib tablets plus everolimus
What this could lead to: If successful, this combination could offer a new second-line treatment option for advanced kidney cancer patients who have already tried immunotherapy.
What could go wrong: This is a phase 3 trial, but it's still early to know if the combination works better than existing options. Side effects from the drugs may occur, and the study is relatively small (116 patients).

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RENAL CELL CARCINOMA (RCC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

renal cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RENAL CELL CARCINOMA (RCC)

Contacts and locations

Locations

Peking University Cancer Hospital

Beijing, Beijing Municipality, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.